Progression of retinal pigment epithelial atrophy in stargardt disease.

PURPOSE To evaluate retinal pigment epithelial (RPE) atrophy in patients with Stargardt disease using autofluorescence imaging (AF). DESIGN Retrospective observational case series. METHODS Demographics, best-corrected visual acuity (BCVA), AF images, and electrophysiology responses (group 1, macular dysfunction; group 2, macula + cone dysfunction; group 3, macula + cone-rod dysfunction) were evaluated at presentation and follow-up in a group of 12 patients (24 eyes) with Stargardt disease. The existence, development, and rate of enlargement of areas of RPE atrophy over time were evaluated using AF imaging. A linear regression model was used to investigate the effects of AF and electrophysiology on rate of atrophy enlargement and BCVA, adjusting for age of onset and duration of disease. RESULTS Eight male and 4 female patients (median age 42 years; range 24-69 years) were followed for a median of 41.5 months (range 13-66 months). All 12 patients had reduced AF compatible with RPE atrophy at presentation and in all patients the atrophy enlarged during follow-up. The mean rate of atrophy enlargement for all patients was 1.58 mm(2)/y (SD 1.25 mm(2)/y; range 0.13-5.27 mm(2)/y). Only the pattern of functional loss present as detected by electrophysiology was statistically significantly associated with the rate of atrophy enlargement when correcting for other variables (P < .001), with patients in group 3 (macula + cone-rod dysfunction) having the fastest rate of atrophy enlargement (1.97 mm(2)/y, SD 0.70 mm(2)/y) (group 1 [macula] 1.09 mm(2)/y, SD 0.53 mm(2)/y; group 2 [macula + cone] 1.89 mm(2)/y, SD 2.27 mm(2)/y). CONCLUSION Variable rates of atrophy enlargement were observed in patients with Stargardt disease. The pattern of functional loss detected on electrophysiology was strongly associated with the rate of atrophy enlargement over time, thus serving as the best prognostic indicator for patients with this inherited retinal disease.

[1]  G. Rubin,et al.  Fixation patterns and reading rates in eyes with central scotomas from advanced atrophic age-related macular degeneration and Stargardt disease. , 1996, Ophthalmology.

[2]  R. Radu,et al.  Light exposure stimulates formation of A2E oxiranes in a mouse model of Stargardt's macular degeneration. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[3]  B. J. Klevering,et al.  The spectrum of retinal phenotypes caused by mutations in the ABCA4 gene , 2005, Graefe's Archive for Clinical and Experimental Ophthalmology.

[4]  A. Bird,et al.  Fundus autofluorescence in Stargardt macular dystrophy-fundus flavimaculatus. , 2004, American journal of ophthalmology.

[5]  R. T. Smith,et al.  Lipofuscin and autofluorescence metrics in progressive STGD. , 2009, Investigative ophthalmology & visual science.

[6]  Dr. K. Stargardt Über familiäre, progressive Degeneration in der Maculagegend des Auges , 1909, Albrecht von Graefes Archiv für Ophthalmologie.

[7]  A. Bird,et al.  Phenotypic subtypes of Stargardt macular dystrophy-fundus flavimaculatus. , 2001, Archives of ophthalmology.

[8]  A. Munnich,et al.  A gene for Stargardt's disease (fundus flavimaculatus) maps to the short arm of chromosome 1 , 1993, Nature Genetics.

[9]  D. Newsome Retinal dystrophies and degenerations , 1989 .

[10]  A. Bird,et al.  Intrafamilial variation of phenotype in Stargardt macular dystrophy-Fundus flavimaculatus. , 1999, Investigative ophthalmology & visual science.

[11]  E. Stone,et al.  CLINICAL PHENOTYPE AS A PROGNOSTIC FACTOR IN STARGARDT DISEASE , 2004, Retina.

[12]  J. Lupski,et al.  A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Starqardt macular dystrophy , 1997, Nature Genetics.

[13]  P. Sieving,et al.  Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[14]  G. Fishman Fundus flavimaculatus. A clinical classification. , 1976, Archives of ophthalmology.

[15]  M. Gorin,et al.  Analysis of autofluorescent retinal images and measurement of atrophic lesion growth in Stargardt disease. , 2010, Experimental eye research.

[16]  D. Bok,et al.  Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases. , 2005, Investigative ophthalmology & visual science.

[17]  A. Krill,et al.  Fundus flavimaculatus. Clinical, functional and histopathologic observations. , 1967, American journal of ophthalmology.

[18]  J. Armstrong,et al.  Long-term follow-up of Stargardt's disease and fundus flavimaculatus. , 1998, Ophthalmology.

[19]  R. M. Carter,et al.  A gold foil electrode: extending the horizons for clinical electroretinography. , 1979, Investigative ophthalmology & visual science.

[20]  Noemi Lois,et al.  Fundus autofluorescence in patients with age-related macular degeneration and high risk of visual loss. , 2002, American journal of ophthalmology.

[21]  M. Bach,et al.  ISCEV Standard for full-field clinical electroretinography (2008 update) , 2009, Documenta Ophthalmologica.

[22]  Jens Dreyhaupt,et al.  Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. , 2007, American journal of ophthalmology.

[23]  T. Aaberg Stargardt's disease and fundus flavimaculatus: evaluation of morphologic progression and intrafamilial co-existence. , 1986, Transactions of the American Ophthalmological Society.

[24]  Robert J. Anderson,et al.  Visual acuity loss and clinical observations in a large series of patients with Stargardt disease. , 2003, Ophthalmology.

[25]  R. Allikmets,et al.  Small molecule RPE65 antagonists limit the visual cycle and prevent lipofuscin formation. , 2006, Biochemistry.

[26]  J. Gass,et al.  Fundus flavimaculatus and Stargardt's disease. , 1976, American journal of ophthalmology.

[27]  Robert Lanza,et al.  EMBRYONIC STEM CELLS / INDUCED PLURIPOTENT STEM CELLS Long-Term Safety and Function of RPE from Human Embryonic Stem Cells in Preclinical Models of Macular Degeneration , 2009 .

[28]  G. Fishman,et al.  The natural history of stargardt disease with specific sequence mutation in the ABCA4 gene. , 2009, Investigative ophthalmology & visual science.

[29]  D. Bok,et al.  Accelerated accumulation of lipofuscin pigments in the RPE of a mouse model for ABCA4-mediated retinal dystrophies following Vitamin A supplementation. , 2008, Investigative ophthalmology & visual science.

[30]  P. Gouras,et al.  Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapy , 2008, Gene Therapy.